Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

Hong Kong’s stock exchange could become a hub for mainland Chinese biotechnology firms thanks to a sweeping reform of listing rules, said the boss of BeiGene, the first such company to take advantage …
( read original story …)

---